Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acquisitions In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cooper Surgical buys Her Option from AMS: American Medical Systems divests its Her Option global endometrial ablation system to Cooper Surgical for $20.5 million in a deal announced Feb. 16. The cryoblation therapy system, which generated about $10 million in sales last year, fits with Cooper Surgical's core strength in the obstetrics/gynecology office space. Meanwhile, the sale of the technology to the Cooper Companies' women's health care unit will allow AMS "to focus our resources on addressing unmet needs in our established pelvic health markets while maximizing the return to our shareholders for this non-strategic asset," AMS explains. Her Option was first approved by FDA in 2001 to treat excessive menstrual bleeding by using extreme cold to ablate the endometrial lining of the uterus. AMS acquired the technology through its purchase of CryoGen in 2002 (1"The Gray Sheet" Dec. 23, 2002). Separately, on Feb. 16, AMS reported fourth-quarter sales of $146 million, up 9% from the same quarter last year

You may also be interested in...



CryoLife Takes Step To Wrest Control Of Reluctant Partner Medafor

CryoLife's purchase of an 8% equity stake in privately held surgical hemostat maker Medafor on Jan. 13 could be the first step of a hostile takeover

AMS’ CryoGen Purchase Anticipates Expanded HerOption Applications

American Medical Systems will seek to extend HerOption endometrial ablation technology for fibroid treatment following the firm's acquisition of CryoGen

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Topics

UsernamePublicRestriction

Register

MT028512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel